Entries |
Document | Title | Date |
20080226674 | Composition Having Antitumor Effect - The present invention is intended to provide a pharmaceutical composition for delivering a chemotherapeutic, preferably an anticancer drug, into cells or into a living organism, using a viral envelope vector, and provides a pharmaceutical composition comprising a chemotherapeutic encapsulated in, or used in combination with, a viral envelope vector having an adjuvanticity as an active ingredient. Thereby it is possible to introduce an anticancer drug encapsulated in a viral envelope vector directly into a tumor, with coadministration of another anticancer drug so as to induce tumor cell-specific antitumor immunity also thanks to the adjuvant action of HVJ-E, and hence to regress the tumor. The present invention also provides a pharmaceutical composition comprising a viral envelope vector and a chemotherapeutic as active ingredients. | 09-18-2008 |
20090041804 | Recombinant vector expressing multiple costimulatory molecules and uses thereof - The present invention is a recombinant vector encoding and expressing at least three or more costimulatory molecules. The recombinant vector may additionally contain a gene encoding one or more target antigens or immunological epitope thereof. The synergistic effect of these costimulatory molecules on the enhanced activation of T cells is demonstrated. The degree of Tell activation using recombinant vectors containing genes encoding three costimulatory molecules was far greater than the sum of recombinant vector constructs containing one costimulatory molecule and greater than the use of two costimulatory molecules. Results employing the triple costimulatory vectors were most dramatic under conditions of either low levels of first signal or low stimulator to T-cell ratios. This phenomenon was observed with both isolated CD4 | 02-12-2009 |
20090123495 | Immune Response Inducing Preparations - The present invention provides a pharmaceutical composition with an adjuvant based on an apathogenic virus, together with an antigen. The adjuvant has a natural or through genetical engineering no, reduced or altered expression of an endogenous interferon antagonist or endogenous immune suppressor. | 05-14-2009 |
20090324641 | NOVEL ADJUVANT COMPOSITIONS - This invention relates to adjuvant formulations comprising various combinations of triterpenoids, sterols, immunomodulators, polymers, and Th2 stimulators; methods for making the adjuvant compositions; and the use of the adjuvant formulations in immunogenic and vaccine compositions with different antigens. This invention further relates to the use of the formulations in the treatment of animals. | 12-31-2009 |
20100003279 | VACCINE FOR IN OVO INOCULATION - A purpose of the present invention is to provide a vaccine for in ovo inoculation effective for prevention of any fowl viral diseases. A fowl vaccine for in ovo inoculation with high efficacy in view of safety as well wherein, by holding such live viruses on a virus-adsorbing agent through adsorption that have been difficult for practical usage as a vaccine for in ovo inoculation, viral growth in embryonated chicken eggs after in ovo inoculation is retarded to thereby reduce pathogenicity of the viruses to embryo to avoid reduction in hatching rate and to alleviate severity in clinical symptoms after hatching. A virus-adsorbing agent to be used in the vaccine includes an aluminum compound such as aluminum hydroxide gel, potassium alum and the like. | 01-07-2010 |
20100028382 | Lentival Vector-Based Vaccine - Methods of eliciting humoral responses, methods of immunization, and methods of vaccination using lentiviral vector are disclosed. Additionally, immunogenic compositions and vaccines for West Nile Virus are disclosed. | 02-04-2010 |
20100166797 | Gammaretrovirus associated with cancer - The present invention provides for isolated nucleic acid sequences encoding viruses; isolated polypeptides comprising amino acid sequences of the virus; vectors comprising the viral nucleic acid sequences; cells comprising the vectors; antibodies and antigen binding fragments thereof which have binding specificity for the virus; methods of detecting or screening for the virus (e.g., in an individual); methods of identifying agents that inhibit the virus; methods of inducing an immune response to the virus; methods of treating disease associated with the presence of XMRV in an individual (e.g., cancer such as prostate cancer); methods of detecting asymptomatic cancer (e.g., prostate cancer); methods of identifying an individual at risk for developing cancer (e.g., prostate cancer); and kits for detecting the virus. | 07-01-2010 |
20100239608 | PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS - The present invention relates to a pharmaceutical composition containing an mRNA that is stabilised by sequence modifications in the translated region and is optimised for the translation. The pharmaceutical composition according to the invention is particularly suitable as an inoculating agent as well as a therapeutic agent for tissue regeneration. In addition a process is described for determining sequence modifications that serve for the stabilisation and translation optimisation of mRNA. | 09-23-2010 |
20100272752 | VACCINE FOR VIRUSES THAT CAUSE PERSISTENT OR LATENT INFECTIONS - The invention is in general directed to methods and compositions for preventing or treating infections by viruses involved in persistent and/or latent infections. The methods and compositions are directed toward the prevention and treatment of infections caused by viruses such as, for example, herpesviruses, retroviruses, hepatitis viruses, and papillomaviruses, including, for example, cytomegalovirus. | 10-28-2010 |
20100285061 | DNA VACCINATION PROTOCOLS - This invention provides DNA vaccines for the treatment of patients undergoing anti-retroviral therapy. The vaccines are surprisingly effective at controlling viremia. | 11-11-2010 |
20100310602 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS - Compounds, particularly, glucopyranosyl lipid adjuvant (GLA) compounds, having the following structure (I) are provided: | 12-09-2010 |
20100322967 | B CELL TOLERANCE INDUCTION - The present invention relates to the induction of immune tolerance, by a novel method of induction of IL-10 production in B cells, whereby said B cells can be loaded with antigen before, during or after the induction of the IL-10 production. More specifically, the invention relates to the transduction of the B cell with a retroviral vector encoding an antigen, whereby the retroviral envelop induces IL-10 production in the B cell by activation the TLR2 receptor, in combination with its viral receptor. | 12-23-2010 |
20110086065 | Lentival Vector-Based Vaccine - Methods of eliciting humoral responses, methods of immunization, and methods of vaccination using lentiviral vector are disclosed. Additionally, immunogenic compositions and vaccines for West Nile Virus are disclosed. | 04-14-2011 |
20110142880 | LENTIVIRUS-BASED IMMUNOGENIC VECTORS - The present invention provides for lentiviral vectors for vaccine delivery comprising a 5′ long terminal repeat (LTR) and a 3′ LTR, an integrated nucleic acid sequence, wherein the integrated nucleic acid sequence is expressed by the 5′ LTR; and a nucleic acid sequence encoding functional REV coding sequence and a rev response element (RRE)-containing sequence, wherein the RRE-containing sequence is located upstream of the REV coding sequence, and wherein transcription of said first nucleic acid sequence and said second nucleic acid sequence is driven by said 5′ LTR. Also provided for are pharmaceutical compositions, methods of making and using the lentiviral vectors of the present invention. | 06-16-2011 |
20110177119 | STABLE, DRIED ROTAVIRUS VACCINE, COMPOSITIONS AND PROCESS FOR PREPARATION THEREOF - The present invention provides novel lyophilized rotavirus vaccine formulations and methods of their preparation. The formulations include vaccine stabilizers, resulting in a vaccine formulation with enhanced stability and minimal loss of potency. The rotavirus vaccine formulations comprise an advantageous ratio of a disaccharide (such as sucrose) to an amino acid (such as glycine). The lyophilization results in a virus formulation with 100% virus preservation and residual moisture from about 0.8% to 1.4%. | 07-21-2011 |
20110223195 | COMPOSITION COMPRISING CHITOSAN FOR OCULAR ADMINISTRATION OF VACCINE(S) TO AVIANS - The invention relates to vaccine compositions comprising chitosan and a vaccine which are administered to avian species via the ocular route, and methods or programs of vaccination including use of chitosan in order to increase or enhance cell-mediated immunity in avian species and persistence of the vaccine avian tissues. | 09-15-2011 |
20110223196 | HIV/SIV VACCINES FOR THE GENERATION OF MUCOSAL AND SYSTEMIC IMMUNITY - Compositions of genetically engineered, secreted gp96 (gp69-Ig) induced strong mucosal and systemic immune responses and CD8 expansion that was independent of CD4 help. Immunization of patients with gp96-Ig immunization is especially attractive for induction of mucosal and systemic immunity to SIV/HIV and other diseases. | 09-15-2011 |
20110268763 | POLYNUCLEOTIDES THAT STIMULATE NEUTROPHILS - The polynucleotides of the present invention are complementary to the Initiation Sites of microbes. Invading organisms, sensing the pH and nutrient deprivation of a physiologic environment quickly release these nucleotides triggering rapid growth and mutation—attributes to successfully establishing a nidus of infection. They also stimulate neutrophil functions. Accordingly, the nucleotides, compositions and methods of the present invention may be used to enhance, restore or stimulate an immune response or system of an animal, e.g. to prevent an infection caused by a microorganism, ameliorate an infection caused by a microorganism, or kill an invading microorganism that causes infection or re-establish balance to an immune system. In particular, the polynucleotides, compositions and methods of the present invention may be used to treat or prevent bacterial infections and auto-immune diseases in a mammal in need thereof. | 11-03-2011 |
20120014989 | PYRROLO[2,3-b]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-b]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS - The present invention provides pyrrolo[2,3-b]pyridine-4-yl amines pyrrolo[2,3-b]pyrimidin-4-yl amines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases and cancer. | 01-19-2012 |
20120039932 | Lentiviral Vectors Pseudotyped with a Sindbis Virus Envelope Glycoprotein - Lentiviral vector particles comprising a Sindbis virus E2 glycoprotein variant and a lentiviral vector genome comprising a sequence of interest are provided. A lentiviral vector particle comprising: (a) an envelope comprising a Sindbis virus E2 glycoprotein variant; and (b) a lentiviral vector genome comprising a sequence of interest; wherein the E2 glycoprotein variant facilitates infection of dendritic cells by the lentiviral vector particle, and wherein the E2 glycoprotein variant has reduced binding to heparan sulfate compared to a reference sequence (HR strain). | 02-16-2012 |
20120213817 | CHIMERIC RSV-F POLYPEPTIDE AND LENTIVIRUS OR ALPHA-RETROVIRUS GAG-BASED VLPS - The present invention relates to chimeric RSV-F polypeptide and lentivirus or alpha-retrovirus GAG-based virus-like particles (VLPs). The present invention also includes methods of making and using such chimeric VLPs. In certain embodiments, the GAG polypeptide of the chimeric VLPs comprises an HIV or ALV GAG polypeptide. | 08-23-2012 |
20130323279 | Human Endogenous Retrovirus Polypeptide Compositions and Methods of Use Thereof - The present invention provides isolated HERV polypeptides; and compositions, including immunogenic compositions, comprising a HERV polypeptide. The present invention provides immunogenic compositions comprising a nucleic acid comprising a nucleotide sequence encoding a HERV polypeptide. The immunogenic compositions are useful for stimulating a T cell immune response to a lentiviral peptide. The present invention further provides methods of stimulating an immune response in an individual to a retrovirus- or lentivirus-infected cell. The present invention further provides methods of treating cancers in which HERV polypeptides are expressed. Also provided are methods of treating disorders, involving decreasing an immune response to a HERV polypeptide. | 12-05-2013 |
20140255445 | SYNTHETIC VIRUSES AND USES THEREOF - The present invention relates to compositions and methods for producing an immune response or reaction, as well as to vaccines, kits, processes, cells and uses thereof. This invention more particularly relates to compositions and methods of using a synthetic viral particle to produce, modify or regulate an immune response in a subject. In a more preferred embodiment, the invention is based, generally, on compositions using synthetic viral particles as an adjuvant and/or vehicle to raise an immune response against selected antigen(s) or epitopes, in particular a cellular and/or a humoral immune response. | 09-11-2014 |
20140286991 | COMBINED CELL BASED GP96-IG-SIV/HIV, RECOMBINANT GP120 PROTEIN VACCINATION FOR PROTECTION FROM SIV/HIV - Compositions are provided comprising heat shock protein, immunoglobulins and retroviral antigens to induce systemic and mucosal immunity to infection from retroviruses such as Human Immunodeficiency Virus (HIV). Methods of treatment provided comprise administration of the compositions, which boost the immune systems response to the retroviral antigens or immunogens. | 09-25-2014 |
20140322268 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS - Compounds, particularly, glucopyranosyl lipid adjuvant (GLA) compounds, having the following structure (I) are provided: | 10-30-2014 |
20140370051 | CHIMERIC NON-INTEGRATING LENTIVIRAL GENOMES AS VACCINES AGAINST HIV-1 - Novel nucleic acids include non-integrative chimeric retroviral genomes including the 5′ and 3′ long terminal repeat sequences (LTRs) of the caprine lentivirus: the Caprine Arthritis Encephalitis Virus (CAEV) or of another retrovirus not integrating human cells and at least one viral gene of another retrovirus. A vector including such a nucleic acid, an immunogenic or vaccinal composition including the vector or the nucleic acid, as well as their use for treating and/or preventing an infection by a retrovirus or a disease induced by a pathogenic agent are also described. | 12-18-2014 |
20160010112 | CYTOMEGALOVIRUS VECTORS ENABLING CONTROL OF T CELL TARGETING | 01-14-2016 |
20160045593 | VACCINE AGAINST BOVINE LEUKEMIA VIRUS - The invention relates to recombinant bovine leukemia viruses that have an attenuated phenotype and comprise a combination of at least two specific mutations. The invention also provides recombinant nucleic acids encoding such viruses, vectors comprising such nucleic acids, and host cells comprising such nucleic acids or vectors. The recombinant attenuated BLV viruses, recombinant nucleic acids, vectors and host cells allow for the preparation of improved vaccines, in particular vaccines suitable for the prophylactic treatment of BLV-associated diseases in subjects. The invention further provides methods for treating BLV-associated diseases in subjects and pharmaceutical compositions suitable for use in these methods. | 02-18-2016 |